Biomarkers in the Diagnosis and Treatment of Covid-19

By
Syeda Shuvessa Kabir
17346036

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of
Bachelor of Pharmacy (Hons.)

School of Pharmacy
Brac University

March 2022

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing degree at Brac University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I have acknowledged all main sources of help.

Syeda Shuvessa Kabir
ID- 17346036



Approval

"Importance of biomarkers in the diagnosis and treatment of COVID-19" submitted by Syeda Shuvessa Kabir (ID-17346036) of Summer 2017 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelors of Pharmacy on 31 March, 2022.

Examining Committee:

Supervisor:
(Member)

_____

Professor Dr. Hasina Yasmin
Deputy Chair, School of Pharmacy
Brac University

Program Coordinator:
(Member)

_____

Namara Mariam Chowdhury
Lecturer, School of Pharmacy
Brac University

Deputy Chair
(Member)

_____

Professor Dr. Hasina Yasmin
Deputy Chair, School of Pharmacy
Brac University

Dean

_____

Professor Dr. Eva Rahman Kabir
Dean, School of Pharmacy
Brac University

Ethics Statement

No animal or human trials have been conducted in this study.

Abstract

Biomarkers are the biological indicators found in body tissue or fluids and can be considered to diagnose any abnormal condition or disease and as a therapeutic target. Identification and clinical application of diverse biomarkers are needed to track the evolution of disease, predict the course of disease, and to monitor patient response to most treatments. Patients with COVID-19 have been observed to have elevated levels of certain biomarkers. Some of the biomarkers related to covid diagnosis and treatment are Serum Ferritin, Procalcitonin, D-dimer, Interleukin-6, Serum Amyloid etc. Various studies have shown that biomarkers can help assess covid seriousness as well. The availability and feasibility of using these biomarkers is sometimes challenging. Our study aimed to focus on the identification of biomarkers in the diagnosis and treatment of COVID-19.

Keywords: Covid-19; Biomarkers; Serum Ferritin, Interleukin 6; Proteinuria; Procalcitonin

Dedication:

I would like to dedicate this thesis work to my parents and my respected teachers who have supported me throughout my education.

Acknowledgement

The completion of this study could not have been possible without the expertise of Professor Dr. Hasina Yasmin, my respected thesis supervisor. I would like to express my sincere gratitude to my advisor for the continuous support on this study, for her patience, motivation, and immense knowledge. Her guidance helped me in all the time of writing of this thesis. Besides, I would like to thank our chairperson Professor Dr. Eva Rahman Kabir for her encouragement and insightful comments.

Table Of Contents

List of Figures

List of Acronyms

SARS	Severe Acute Respiratory Syndrome
RT-PCR	Reverse Transcriptase Polymerase Chain Reaction
AKI	Acute Kidney Injury
NCIP	Novel Corona infected Pneomonia
COVAN	COVID 19 related nephropathy
UPCR	Urinary Protein Creatinine Ratio
AIC	Area Under Curve
IL 6	Interleukin 6
CRP	C reactive protein
PCT	Procalcitonin
SA	Serum Amyloid
hs-Tn I	High Sensitivity cardiac troponin I
MDW	Monocyte Dispersion Width
ADM	Adrenomedullin

Chapter 1: Introduction

1.1 COVID-19

The severe acute respiratory syndrome coronavirus-2 (SARS) relates to a novel kind of corona virus which belongs to Coronaviridae family. It is also proved to be solely responsible for outbreak of some acute atypical respiratory infections. The virus causing disease was named as COVID-19 or Coronavirus-19. In 10th March, 2020 WHO stated that this coronavirus disease is highly spreading throughout the world and thus termed it as pandemic (Chauhan, 2020; Liu et al., 2020; Shih et al., 2020).

For diagnosing coronavirus infection there are some tools that have been using so far. For instance-

i. Detection of human antibody
ii. Detection of viral gene
iii. Detection of viral antigen

Among all of these techniques detection of the viral gene that is done with RT-PCR is considered as the most convenient technique. In addition, CT scan of chest accompanied by laboratory test is also effective for coronavirus diagnosis for people having greater infection suspicion (Etienne et al., 2021). Scientists and researchers are still trying for producing new drugs as well as testing drugs that are already existing to determine if they can properly fight against covid. Meanwhile there are some drugs available that can minimize the pain in hospital and home. In case of treating covid at home, when symptoms are mild patients can fully recover at home. They should take enough rest that will help speed recovery. They should always stay at home isolated and avoid going to school, college, office or another public place. If patients lose more water, they will get sick easily. Dehydration can worsen the situation thus lead to various health complications (Afrin et al., 2021). If complications rise, the doctor should be called without any delay. Doctor might advise to stay at home or take other necessary steps

that will ensure the safety of other patients' ad stuffs in the hospital. Moreover, the doctor can be asked regarding the over-the-counter medication. For instance- Acetaminophen can easily reduce fever and pain (K Geetha, 2021). If we want to protect ourselves and our near ones from getting infected by coronavirus, firstly we need to stop touching the surface most importantly in public places or healthcare places since there is a possibility that a covid patient might have touched the surface before. Secondly, the surfaces need to be cleaned on a daily basis with appropriate disinfectants. Lastly, our hands must be cleaned with clean water, hand rub or sanitizer (Andersen et al., 2020).

1.2 Biomarkers

Biomarkers relate to specific biological markers that can determine any abnormality that is happening within the body tissues. When a person faces any kind of disease the level of biomarkers gets higher and this increased biomarker help identify the diagnosis of disease also. Several examples of biomarker include- blood pressure, heart rate, d dimer, LDG, ferritin etc. (Gerbeau et al., 2018). Everything that we obtain from blood pressure and pulse, various complex laboratory testing using blood and several other tissues are also categorized as biomarkers. Biomarkers can be quantified, they are the highest objective, they provide the signs by which modern clinical science can easily measure any disease condition. These medical signs have previously been used in medical and clinical practice as well. The idea of using biomarkers in research or in laboratory is quite new. Scientist are still trying to identify and refine newer methodologies. Because of this there are some challenges that are coming up for example- getting any association between biomarker which is quantified as well as clinical endpoint which will be relevant (Tang et al., 2021).

Biomarkers play an important role in identifying early signs and symptoms, prevention, toxicity, diagnosis as well as drug response of the disease. During the time of diagnosis

cerebrospinal fluid, urine, blood is generally used for getting the basic information regarding the disease (Chen et al., n.d.). Biomarker research has become very significant in today's era of biomedical research. The biomarker term was initially obtained from these two words "biological" as well as "marker" and presently it connects to numerous physiological activities and substances. Biomarkers are basically measured property that are objectively evaluated and can highly act as indicator for general biological procedures, pharmacologic, therapeutic or pathologic response. (National Institutes of Health USA, 2001). This is why biomarkers can also be used in prognosis, screening and diagnosis (Fuentes-Arderiu, 2013). Diagnosis of Coronavirus has also been very rapid and fast by monitoring biomarker level. Recently there are numerous corona biomarkers that have been identified (J. Huang et al., n.d.). For instance- post anticoagulant D dimer, serum amyloid, c reactive protein, ferritin, procalcitonin, proteinuria and so on (de Bruin et al., 2021).

1.3 Rationale of the study

Biomarkers are generally applied to predict any disease outcome which will eventually help the treatment procedure as well as interventions. In maximum case, biomarkers provide highest safety and efficacy in determining diseases. Even in case of covid also, biomarkers might play several roles starting from identifying patient's deviation from normal condition to giving the staging for the disease extent. In addition, response monitoring to any intervention can be accomplished by biomarkers.

Under all these circumstances this review article study has been conducted to determine the basic idea of biomarkers, their features, important characteristics, their use in covid treatment and diagnosis as well as their future scope in clinical and research fields.

1.4 Aim of the study

The aim of this review article is to identify biomarkers in diagnosis and treatment of covid-19.

Chapter 2: Methodology

This review paper has been conducted based on recent and relevant research papers and articles from peer reviewed journals. A comprehensive search has been performed through peer-reviewed journals, clinical trial reports and articles. To enrich the review paper, basic and additional information have been collected from different books. Following search engines have been used to collect data for this paper- ResearchGate, Science Direct, PubMed, Elsevier, etc. in which the major publications include- Nature, ACS (American Chemistry Society), IDI (Infectious Disease Institute), Molecular Cell, Journal of Global Infectious Disease, Journal of Medicine, Science, etc. In-depth screening of the journals followed by narrowing down to the most recent and relevant ones was done to create an ideal quality review on the potentialities of biomarkers in the context of COVID-19.

Chapter 3: COVID-19

3.1 Pathophysiology

Coronavirus affects the gastrointestinal tract and upper respiratory tract of both birds and mammals. Five to six several presently known coronavirus strains affect humans. The highest publicized human coronavirus, SARS-CoV that creates SARS, possesses a unique pathogenesis since this creates both lower and upper respiratory tract infections and might create gastroenteritis (Khan et al., 2021a). Coronavirus is thought to create a particular percentage among all types of common colds into human adults. Coronavirus creates colds in humans basically in winter and also in early spring. The economic impact as well as significance of coronavirus as causative agent common cold is difficult to assess since unlike the rhinovirus (one kind of common cold virus), human coronavirus is hard to grow in laboratory (Khan et al., 2021a).



Figure 1: Pathophysiology of Coronavirus (Zildzic et al, 2020).

These viruses affect several mammals as well as birds. Overall number of human isolates cannot be identified since they are not grown in culture. They can create different infections in human: For example- Common respiratory infections that include rare syndromes that are

neurological, severe acute respiratory syndrome (SARS), occasional infections which happens in children less than twelve months (Hodges et al., 2020).

3.2 Signs and symptoms

Basically, cytokine storm is all about maximum number of cytokines getting released and creating inflammation in very high level. In this case, cytokines generally try to signal immune system for getting back its general activity, while the flow will be a little bit higher. Cytokines play a very significant role in humans. If they get connected to any route in body in an excess level, the patients can get harmed by the immune system. Similarly in terms of covid, the infection is followed by the release of vast number of cytokines which is pro inflammatory (Herr et al., 2021).



Figure 2: Cytokinin storm related to coronavirus (Herr et al, 2021).

Covid patients show several ranges of signs along with symptoms starting from mild to very severe. These signs and symptoms may tend to appear two to sixteen days just after the virus exposure (Wendel Garcia et al., 2020). Any corona patient may have slight to heavy serious symptoms. The most common symptoms include

- Diarrhea
- Vomiting
- Nausea
- Cough
- Fever
- Muscle pain
- Aches
- Headache
- Shortness or difficulty in breathing
- Fatigue
- Chills

Other symptoms include:

- Pinkish eyes
- Sore throat
- Taste loss
- Smell loss
- Stuffy nose
- Toes or fingers discoloration
- Rashes

3.3 Treatment and prevention

The doctors and healthcare providers should only offer and prescribe the treatment related to covid. In some cases, patients had to die because of taking the drugs which did not get approved for covid or taking the drugs that are used for other purposes. Recently FDA (Food and Drug

Administration) has given approval to a drug named Remdesivir (Veklury) to fight against corona virus.

FDA may issue EUAs (Emergency Use Authorization) for allowing doctors for applying the medicines which have not yet received approval or which are applied for other purposes, to provide treatment to corona patients if only they fulfill all the legal requirements. NIH (National Institutes of Health) is very much active in terms of updating the treatment guidelines that help the doctors to get the proper guidance in regards to corona treatment (Hashemi et al., 2021; Zildzic et al., 2020). Recently there are several vaccines that gave got approval and are proved to be effective to treat covid such as Pfizer- BioNTech, Moderna, AstraZeneca. Vaccination is one of the most convenient ways to prevent from corona virus.

Chapter 4: Biomarkers in Covid 19

Till now scientists and researchers have found some biomarkers that will be helpful in the diagnosis of covid. They are also trying to identify if these markers can help in the treatment of covid as well. Not all biomarkers can lead to the diagnosis as well as treatment of covid. It has been seen that some of them can be used in the treatment, some of them in the diagnosis and some of them in both cases.

Name	Function
1. Serum Ferritin	Prognostic biomarker, indicates covid seriousness
2. Proteinuria	Indicator of covid
3. C Reactive Protein	Diagnosis & Treatment
4. D Dimer	Diagnosis
5. Procalcitonin	Diagnosis & Treatment
6. Interleukin 6	Diagnosis
7. Serum Amyloid A	Treatment
8. Cardiac Troponin	Diagnosis
9. Lactate dehydrogenase	Diagnosis
10. Renal biomarkers	Diagnosis
11. Immunological biomarkers	Treatment
12. Other biomarkers	Treatment

4.1 Serum Ferritin



Figure 3: Serum Ferritin levels in covid and non-covid person (Das et al., 2021).

Serum ferritin by and large addresses a biomarker of decision when iron shows infections. We then, at that point, contrasted these outcomes and nine current COVID-19 ferritin reports distributed in 2020. A few non-irresistible, just as non-COVID-19 irresistible sicknesses, are described by a mostly sensational height of serum ferritin levels. All COVID-19 investigations distributed among February and May 2020, which reported research center serum ferritin, show ferritin as biomarker of corona seriousness in patients who are hospitalized. Serum ferritin might be considered both a prognostic and separating biomarker that can likewise add to restorative independent direction concerning patients with COVID-19. It ought to be underscored, in any case, that most logical reports allude to partners in the Asian area. Further approval in different partners is critically required.

4.2 Proteinuria

Upper respiratory and pneumonic sicknesses are the essential appearances of Covid infection 2019 (COVID-19). In any case, kidney association has additionally been perceived and broadly depicted. An enormous level of impacted patients who have intense injury of kidney. In any case, explicit phenotypic parts related to AKI and other indications of being covid positive are inadequately portrayed. Several researchers demonstrate proteinuria is identified in kidney

injury related to CoV-AKI notwithstanding CoV-AKI becoming a great extent portrayed as a type of intense rounded injury. Then again, people of African family line with great hazard genotype APOL1 belong to interestingly in danger to create falling glomerulopathy while they get contaminated with the extreme intense respiratory disorder Covid 2, this element presently called COVID-19-related to nephropathy (Also called COVAN). People who have COVAN ordinarily show proteinuria which is nephrotic ranged (Caruso et al., 2021). The specific occurrence of this proteinuria in corona is muddled because of the heterogeneity in recurrence along with which proteinuria is evaluated into the instances of corona, since strategic contrasts in the manner in which proteinuria is estimated and additionally detailed. In this survey we talk about present proof of this proteinuria as a corona indicator as well as expand on the pathophysiological components related to this (Ouahmi et al., 2021).



Figure 4: Proteinuria level changes in disease progression (Pu et al., n.d.).

Renal inclusion in SARS-CoV-2 contamination has been reflectively portrayed, particularly intense injury of kidney. Nonetheless, quantitative amount of proteinuria appraisal as well as suggestion for corona virus stay obscure. Multicenter kind of study that was performed in Paris, clinical as well as organic information was gathered that included proportion of urinary protein-creatine (UPCR) in people giving medium to extreme covid. Result had been investigated by UPCR degree.

43/46 patients (92.4%) got renal contribution (unusual urine residue and also additionally acute kidney injury). Critical proteinuria occurred in 62% people. Pee electrophoresis protein proved rounded discharge of protein in 84.6% people having proteinuria. Fiery boundaries and d-dimer focuses connected to level of proteinuria. People who needed emergency affirmation showed greater level of proteinuria (p = 0.007).

4. 3 Reactive protein C



Figure 5: Structure of C reactive protein (Tom et al, 2021).

Information for foreseeing seriousness of corona patients' contamination remain scanty as well as being scrutinized. Researchers reflectively concentrated if this level of serum C confirmation serum C-responsive level of protein might fill in as an almost indicator for illness seriousness in time of corona disease on examination along with several fiery and hematologic markers (Tom et al., 2021). This investigation discovered the level of CRP on confirmation

address straightforward as well as free variable which might be helpful on primary location of seriousness in corona along with simple direction on essential consideration.

C Reactive Protein belongs to a plasma protein created through liver as well as instigated through different fiery go between, for example, IL-6. In spite of being vague, this intense stage reactant gets utilized clinically as biomarker for several provocative conditions; one ascent in C Reactive Protein levels is associated to the increment into infection seriousness (Valerio et al., 2021).

The use of C Reactive Protein in covid is featured through a single review focus study in China where most people in extreme companion presented essentially more significant level contrasted with non-serious accomplice (56.8 mg/L versus 34.3 mg/L, $P < 0.001$). Another review companion concentrates on tracked down the probability of advancing to extreme COVID-19 sickness expanded in people with C Reactive Protein level >42.6 mg/L. These investigations recommend the level of C Reactive Protein are a solid pointer to mirror the seriousness and presence of covid disease.

4.4 D Dimer



Figure 6: Impacts of D-dimer in covid infection (Malik et al., 2021).

Covid is a principally respiratory sickness which might create thrombotic messes. Increased D-dimer can be a potential marker for the helpless visualization in covid, however ideal cut off an incentive for this D-dimer for anticipating mortality is not set up yet. The review expects to survey exactness for confirmation D-dimer into forecast of covid and for setting up ideal cut off D-dimer worth for anticipating emergency clinic mortality (I. Huang et al., 2020; Yael Becher et al., 2020).

Clinical and research center boundaries and results of affirmed covid case conceded to five medical clinics in Nepal were reflectively broke down. Conceded covid cases along with recorded level of D-dimer as well as conclusive results had been incorporated sequentially. D-dimer level has been estimated utilizing immunofluorescence measure as well as announced in fibrinogen equivalent unit (mg./ml) (Song et al., 2021).

The beneficiary working trademark bend was utilized to decide the precision of D-dimer into anticipating mortality as well as for computing ideal cut off esteem, in light of which people had been isolated in three gatherings as well as prescient worth of this D-dimer for the mortality has been estimated. Results 183 people were remembered for concentrate out of this 36(19.3%) passed on during emergency clinic staying (I. Huang et al., 2020).

This D-dimer began through lysis of cross connected fibrin along with rising level demonstrating enactment of fibrinolysis as well as coagulation. Primary examinations had related covid with hemostatic irregularities with a review noticing raised degrees of the D-dimer, the coagulation proportion, in the non-survivor people contrasted with the survivors (Yao et al., 2020; Ye et al., 2020).

4.5 Procalcitonin



Figure 7: Structural representation of procalcitonin molecule (Rochwerg et al., 2020).

The serum procalcitonin level as marker for several bacterial co contamination as well as infection seriousness in covid people (Richards et al., 2021). The increase in absolute serum level of this Procalcitonin has been seen with seriousness of sickness ($p < 0.04$). This factual examination addressed no other relationship of Procalcitonin esteem along with sexual orientation (p 0.9724) while uncovered a slight critical affiliation ($p < 0.001$) with age as well as Procalcitonin esteem in covid people.

This tends to get presumed that sequential procalcitonin estimation might decide forecast of sickness as well as presence of several bacterial co contamination in covid people. More investigation of this point is expected for assessing impact of various treatments on Procalcitonin level as well as for recommending explicit treatments choice for the coinfection (Cavalier et al., 2021).

The level of Procalcitonin apparently increased in people having serious sickness contrasted and non-extreme covid people, reflecting different bacterial super contamination. The level of Procalcitonin does not transcend the ordinary reach in people having non-muddled covid, accordingly addressing an applicant marker for genuine infection movement. However, prognostic worth of Procalcitonin in covid people gets questioned, as this is inside generally expected reach into many people at starting show.

4.6 Interleukin



Figure 8: Interleukin level changes during covid (Zhang et al., 2020).

Past reviews showed that raised degree of Interleukin-6 was related to high case casualty of covid disease (Sivakorn et al., 2021).

4.7 Serum Amyloid

High groupings of serum amyloid A related with higher COVID-19 seriousness and mortality have been observed in a recent survey. This survey dissected nineteen investigations comprising of north of 5,000 patients with COVID-19. The pooled outcomes showed that serum amyloid A focuses were fundamentally higher in those patients with serious illness and

non-survivors. This estimation could be helpful for hazard delineation and clinical observing of these patients (Zakeri et al., 2021).



Figure 9: Serum amyloid and the basic function (Cho et al, 2016).

Coursing SAA focuses, commonly low under physiological conditions (20–50 mg/l), can increment up to 1000-overlap inside the initial 24–48 h of an intense stage reaction (Zinellu et al., 2021). It is mainly outcome of expanded blend in liver that gets set off through a few boosts, which includes TNF, Interleukin (IL)- 1β, Iinterleukin-6, and Interferon Gamma (IFN-γ). SAA, thusly, can initiate the supplement framework as well as nucleotide-restricting space leucine rich rehash which contains pyrin area having 3 (NLRP3) inflammasome, more increment this amalgamation on TNF, Interleukin-1β, Interleukin-6, as well as actuate other proinflammatory cytokine, for example, Interleukin-1α and Interleukin-23. (Gonçalves & Sesterheim, 2021).

Two methodical audits as well as meta examinations on somewhat set several numbers of the studies, four and five, individually, announced critical as well as positive relationship between

Serum Amyloid A focuses as well as covid seriousness. Following the distribution of a few extra investigations, a refreshed precise audit as well as meta examination had been directed of accessible proof on clinical ramifications of Serum Amyloid A focuses in people having covid (Gonçalves & Sesterheim, 2021).

4.8 Cardiac troponin



Figure 10: Molecular view of troponin (Zinellu et al., 2021).

COVID-19 infection has been linked to a greater mortality risk in people with underlying cardiovascular disease. High Sensitivity Cardiac Troponin I (hs-TnI) have been studied as measure for disease progression as well as death. In the retrospective investigation of people being positive for covid according to SARS-CoV-2 RNA identification in China, univariable odd ratio on mortality for hs-TnI was found to be 80.1 (95 percent CI 10.3–620.4, p0.0001). When it was compared to different other markers like lymphocyte count as well as D-Dimer, this risk was larger. Another research of 416 COVID-19 patients in hospitals found that 1 in 5 patients had increased hs-TnI at the time of admission (Mueller et al., 2021; Omland et al., 2021). The use of inotropes and vasopressors is informed by early detection of myocardial damage as shown by raised hs-TnI (Stefanini et al., 2020). Elevated levels, on the other hand, are very common in people who are hospitalized as well as are most likely

attributable on non-ischemic myocardial damage (Sheth et al., 2021). This could lead to erroneous cardiology consultations and downstream testing, putting cardiac physiology professionals at risk.

4.9 Lactate dehydrogenase



Figure 11: Biochemical and clinical significance of Lactate Dehydrogenase (Bivona et al, 2021).

In glucose digestion, the protein LDH changes over Pyruvate to Lactate. Lactate Dehydrogenase emission is set off through putrefaction of cell layer, implying on viral contamination and lung harm, for example, pneumonia initiated through SARS-CoV-2. Here is persuading proof connecting Lactate Dehydrogenase level to improvement of covid infection. One review tracked down fundamentally more elevated level of Lactate Dehydrogenase in people who were in ICU than people who were not in ICU (247 U/L versus 152 U/L, p=0.001). As significant degrees of Lactate Dehydrogenase proceeded in ICU people's days number post confirmation (170 U/L versus 219 U/L, p=0.001), Lactate Dehydrogenase might be prescient marker of serious infection. In any case, the one community study might be inclined to choose inclination which might actually lessen its

legitimacy (Bivona et al., 2021). One multi focus study including 1095 people announced supporting proof corresponding degree of the tissue harm as well as aggravation through expanding Lactate Dehydrogenase level, Moreover, when Lactate Dehydrogenase level was connected to CT filters, essentially more significant levels mirrored the pneumonia seriousness. Here is expanding trust into involving Lactate Dehydrogenase as biomarker for quantifying seriousness of covid contamination. One other investigation discovered that there had been huge ascent in the Lactate Dehydrogenase level among unmanageable covid people (al Shaqsi et al., 2020).

4.10 Renal biomarkers

Recently some additional proves have been found that persistent kidney illness is somehow related to serious types of COVID-19 disease.

Studies have shown altogether more elevated renal marker levels like creatinine, serum urea as well as biomarkers for rate of glomerular filtration in serious case. As the outcomes originate from examination of 27 patients, extrapolation through bigger companions gets troublesome.

Strangely, another review showed an expected job of urinalysis over the serum biomarkers of kidney work. The irregularities in normal pee tests on confirmation corresponded firmly with the illness seriousness. Basically, they proceed to recommend that urinalysis might uncover kidney impedance more promptly than assessment on serum renal markers. Nonetheless, the tests were mainly done for confirmation thus people in prior phases of contamination possessed changes in the serum level clouded through compensatory kidney work. Henceforth renal marker anomalies on the affirmation might show greater dangers of the decay, guaranteeing suitable triaging (Morell-Garcia et al., 2021).

While surveying a person having covid contamination, biomarkers might be helpful for any clinician in beginning the treatment as well as close observing. However, markers might assist

with further developing anticipation and results, their huge fluctuation between patients could influence the discoveries of the examinations. This work till date recommends there is obvious proof on how degrees of these biomarkers might change as per seriousness of covid disease. It might be utilized as any aide for the clinical practice for directing treatment as well as admission to ICU. Thusly, this might further develop guess and limit the death rates (al Shaqsi et al., 2020).

4.11 Immunological biomarkers

The White Blood Cells count, incorporating the normal cells, lymphocyte, neutrophil to lymphocyte ratio as well as lymphocyte subset have been surveyed in covid people, alongside cytokine profile. A few examinations had detailed that the lymphopenia, neutrophilia T assistant (CD4+) as well as T cytotoxic (CD8+) lymphocyte consumption and also neutrophil to lymphocyte ratio increment are firmly connected to infection seriousness. Different investigations have detailed that lymphocyte as well as normal cells possess low prognostic exactness than C Reactive Protein in recognizing serious as well as non-extreme covid case. This dependability of white blood cell count, normal cell and lymphocyte is fairly questioned as immunological biomarkers might be impacted through several variables, which includes glucocorticoid treatment as well as bacterial or viral diseases focusing on lymphoid tissue. Thus, fluctuation in the lists cannot be obscurely ascribed to level of covid seriousness (Elshazli et al., 2020).

Among the cytokines, IL-6 has drawn specifically consideration as for COVID-19. A few examinations have shown a relationship between Interleukin-6 level as well as sickness seriousness in covid people. Greater gauge Interleukin-6 level in extreme covid positive people were emphatically connected to the requirement of mechanical ventilation, lung harm on the CT filters as well as other provocative biomarkers including C Reactive Protein, Ferritin as

well as D-dimer. Another new meta investigation uncovered that Interleukin-6 level had almost four-overlay greater in extreme covid people than in non-serious people. (Marimuthu et al., 2021; Sivakorn et al., 2021) In any case, various results are considered in examinations assessed in the meta investigation (ARDS, emergency unit affirmation, and demise), making it hard to decide explicit Interleukin-6 level which led to the given result. As to unwavering quality of Interleukin-6 as treatment reaction biomarker, showed that IL-6 levels don't essentially shift between sarilumab responder as well as non-responder. In this manner, helpfulness of Interleukin-6 as biomarker of treatment reaction isn't demonstrated. One more report showed that Interleukin-6 level diminished after the treatment along with anti-microbials, glucocorticoids as well as antivirals, yet didn't indicate whether pattern levels could foresee treatment reaction (Marimuthu et al., 2021).

4.12 Other biomarkers

Lactate Dehydrogenase and Serum Amyloid A are likewise significant up-and-comer markers for covid. A few examinations have presented that ICU covid positive patients have altogether greater Lactate Dehydrogenase level than non-ICU covid people and the Lactate Dehydrogenase level connected to tissue harm as well as CT check scores, that reflects infection seriousness. Furthermore, Lactate Dehydrogenase levels are higher in people requiring mechanical ventilation just as antiviral treatment as well as extra corticosteroid.

In addition, MiRNAs belong to non-coding RNAs that tight spot to objective mRNA arrangement, managing quality articulation at post transcriptional level. Numerous cell processes including separation, expansion, as well as endurance get managed by the miRNAs. During the diseases, cell miRNAs might collaborate with infections as well as might assume any part in antiviral resistant reaction Hence, job of miRNAs as likely markers in covid is examined, uncovering 35 positive sense and 46 negative sense miRNAs which unequivocally

tie to the key SARS-CoV-2 qualities. Creators theorized that miRNAs might get valuable for screening the infection in various stages as well as anticipate illness course. In any case, strong proof still needs to be given (Gogate et al., 2020; Whetton et al., 2020).

Chapter 5. Conclusion

To conclude, several types of biomarkers have been utilized by scientists and researchers till now to analyze their role in covid preliminaries. These biomarkers provide advantages in the improvement of corona immunization as well. They additionally help in directing subject determination and decreasing patient dangers. Recently two types of markers belonged to symptomatic biomarkers are being utilized in corona preliminaries. Moreover, biomarkers like C-Reactive Protein, Interleukin-6, Serum Amyloid A, Procalcitonin have been additionally accounted for getting used in the diagnosis and treatment of covid. Investigators of Global Data have stated that biomarkers are proved to be helpful in fast races for distinguishing serious instances of corona. Basically, these biomarkers are valuable in deciding the sort of medications which may be regulated in treating patients of corona virus. Also, biomarkers are assuming an urgent path both in directing upgrades in administration of corona patients and overall antibody improvement endeavors. All the experiments with biomarkers for covid diagnose and treatment is yet in its beginning phases. The revelation of how unique biomarkers act throughout covid sickness can really help researchers and clinicians in distinguishing extreme corona sickness. Eventually this will lead to further development of biomarkers in the diagnosis as well as treatment of covid patients worldwide (Tabassum et al., 2021).

References

Afrin, S. F., Rahman, M. H., Mahmood, A. K. al, Salma, N., & Khatun, S. (2021). Assessment of covid severity by measuring d-dimer and serum ferritin level in selected tertiary care hospitals of Dhaka city. *Bangladesh Journal of Medical Science*, *20*(5), 166–170. https://doi.org/10.3329/BJMS.V20I5.55409

al Shaqsi, N. H. K., al Hoqani, H. A. S., Hossain, M. A., & al Sibani, M. A. (2020). Isolation, characterization and standardization of demineralization process for chitin polymer and minerals from the crabs waste of Portunidae segnis. *Advances in Biomarker Sciences and Technology*, *2*, 45–58. https://doi.org/10.1016/j.abst.2020.10.002

Alberca, R. W., Solis-Castro, R. L., Solis-Castro, M. E., Cardoso, F., da Silva Duarte, A. J., de Mendonça Oliveira, L., Pereira, N. Z., Gozzi-Silva, S. C., Araujo de Oliveira, E., Aoki, V., Orfali, R. L., Beserra, D. R., de Souza Andrade, M. M., & Sato, M. N. (2021). Platelet-based biomarkers for diagnosis and prognosis in covid-19 patients. *Life*, *11*(10). https://doi.org/10.3390/life11101005

Amur, S. (n.d.). *BIOMARKER QUALIFICATION PROGRAM EDUCATIONAL MODULE SERIES-MODULE 1 BIOMARKER TERMINOLOGY: SPEAKING THE SAME LANGUAGE*. www.fda.gov

Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020). The proximal origin of SARS-CoV-2. In *Nature Medicine* (Vol. 26, Issue 4, pp. 450–452). Nature Research. https://doi.org/10.1038/s41591-020-0820-9

Bivona, G., Agnello, L., & Ciaccio, M. (2021). Biomarkers for prognosis and treatment response in covid-19 patients. In *Annals of Laboratory Medicine* (Vol. 41, Issue 6, pp. 540–548). Seoul National University, Institute for Cognitive Science. https://doi.org/10.3343/ALM.2021.41.6.540

Calvo-Fernández, A., Izquierdo, A., Subirana, I., Farré, N., Vila, J., Durán, X., García-Guimaraes, M., Valdivielso, S., Cabero, P., Soler, C., García-Ribas, C., Rodríguez, C., Llagostera, M., Mojón, D., Vicente, M., Solé-González, E., Sánchez-Carpintero, A., Tevar, C., Marrugat, J., & Vaquerizo, B. (2021). Markers of myocardial injury in the prediction of short-term COVID-19 prognosis. *Revista Española de Cardiología (English Edition)*, *74*(7), 576–583. https://doi.org/10.1016/j.rec.2020.09.011

Caruso, F. P., Scala, G., Cerulo, L., & Ceccarelli, M. (2021). A review of COVID-19 biomarkers and drug targets: Resources and tools. In *Briefings in Bioinformatics* (Vol. 22, Issue 2, pp. 701–713). Oxford University Press. https://doi.org/10.1093/bib/bbaa328

Cavalier, E., Guiot, J., Lechner, K., Dutsch, A., Eccleston, M., Herzog, M., Bygott, T., Schomburg, A., Kelly, T., & Holdenrieder, S. (2021). Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression. *Frontiers in Molecular Biosciences*, *8*. https://doi.org/10.3389/fmolb.2021.600881

Chauhan, S. (2020). Comprehensive review of coronavirus disease 2019 (COVID-19). In *Biomedical Journal* (Vol. 43, Issue 4, pp. 334–340). Elsevier B.V. https://doi.org/10.1016/j.bj.2020.05.023

Chen, X.-H., Huang, S., & Kerr, D. (n.d.). *Unit 4 • Chapter 17. Biomarkers in clinical medicine Biomarkers in clinical medicine*.

Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., Cheng, W.-W., Ma, V. W. S., & Lim, C. K. P. (2004). *Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling*. www.matrixscience.com/home.html.

Ciaccio, M., & Agnello, L. (2020). Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). In *Diagnosis* (Vol. 7, Issue 4, pp. 365–372). Walter de Gruyter GmbH. https://doi.org/10.1515/dx-2020-0057

Das, B., Bhatia, S. Y., & Pal, P. M. (2021). Evaluation of the Role of Routine Laboratory Biomarkers in COVID-19 Patients: Perspective from a Tertiary Care Hospital in India. *Indian Journal of Clinical Biochemistry*, *36*(4), 473–484. https://doi.org/10.1007/s12291-021-00978-x

de Bruin, S., Bos, L. D., van Roon, M. A., Tuip-de Boer, A. M., Schuurman, A. R., Koel-Simmelinck, M. J. A., Bogaard, H. J., Tuinman, P. R., van Agtmael, M. A., Hamann, J., Teunissen, C. E., Wiersinga, W. J., (Koos) Zwinderman, A. H., Brouwer, M. C., van de Beek, D., & Vlaar, A. P. J. (2021). Clinical features and prognostic factors in Covid-19: A prospective cohort study. *EBioMedicine*, *67*. https://doi.org/10.1016/j.ebiom.2021.103378

Elshazli, R. M., Toraih, E. A., Elgaml, A., El-Mowafy, M., El-Mesery, M., Amin, M. N., Hussein, M. H., Killackey, M. T., Fawzy, M. S., & Kandil, E. (2020). Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. *PLoS ONE*, *15*(8 August). https://doi.org/10.1371/journal.pone.0238160

Etienne, E. E., Nunna, B. B., Talukder, N., Wang, Y., & Lee, E. S. (2021). Covid-19 biomarkers and advanced sensing technologies for point-of-care (Poc) diagnosis. In *Bioengineering* (Vol. 8, Issue 7). MDPI AG. https://doi.org/10.3390/BIOENGINEERING8070098

Farid, E., Sridharan, K., Alsegai, O. A. M., Khawaja, S. al, Mansoor, E. J., Teraifi, N. A., Qahtani, M. al, & Salman, J. al. (2021). Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience. *Biomarkers in Medicine*, *15*(8). https://doi.org/10.2217/bmm-2020-0422

Fuentes-Arderiu, X. (2013). What is a biomarker? It's time for a renewed definition. In *Clinical Chemistry and Laboratory Medicine* (Vol. 51, Issue 9, pp. 1689–1690). https://doi.org/10.1515/cclm-2013-0240

Gerbeau, J. F., Lombardi, D., & Tixier, E. (2018). How to choose biomarkers in view of parameter estimation. *Mathematical Biosciences*, *303*, 62–74. https://doi.org/10.1016/j.mbs.2018.06.003

Gogate, N., Lyman, D., Crandall, K. A., Kahsay, R., Natale, D. A., Sen, S., & Mazumder, R. (2020). COVID-19 Biomarkers in research: Extension of the OncoMX cancer biomarker data model to capture biomarker data from other diseases. *BioRxiv : The Preprint Server for Biology*. https://doi.org/10.1101/2020.09.09.196220

Gonçalves, C. A., & Sesterheim, P. (2021). Serum amyloid A protein has been undervalued as a biomarker of COVID-19. In *Diabetes/Metabolism Research and Reviews* (Vol. 37, Issue 1). John Wiley and Sons Ltd. https://doi.org/10.1002/dmrr.3376

Harahwa, T. A., Lai Yau, T. H., Lim-Cooke, M. S., Al-Haddi, S., Zeinah, M., & Harky, A. (2020). The optimal diagnostic methods for COVID-19. In *Diagnosis* (Vol. 7, Issue 4, pp. 349–356). Walter de Gruyter GmbH. https://doi.org/10.1515/dx-2020-0058

Hashem, M. K., Khedr, E. M., Daef, E., Mohamed-Hussein, A., Mostafa, E. F., Hassany, S. M., Galal, H., Hassan, S. A., Galal, I., Amin, M. T., & Hassan, H. M. (2021). Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer. *The Egyptian Journal of Bronchology*, *15*(1). https://doi.org/10.1186/s43168-021-00075-w

Hashemi, B., Akram, F. A., Amirazad, H., Dadashpour, M., Sheervalilou, M., Nasrabadi, D., Ahmadi, M., Sheervalilou, R., Ameri Shah Reza, M., Ghazi, F., & Roshangar, L. (2021). Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19

patients. In *Journal of Drug Delivery Science and Technology*. Editions de Sante. https://doi.org/10.1016/j.jddst.2021.102967

Herr, C., Mang, S., Mozafari, B., Guenther, K., Speer, T., Seibert, M., Srikakulam, S. K., Beisswenger, C., Ritzmann, F., Keller, A., Mueller, R., Smola, S., Eisinger, D., Zemlin, M., Danziger, G., Volk, T., Hoersch, S., Krawczyk, M., Lammert, F., … Bals, R. (2021). Distinct patterns of blood cytokines beyond a cytokine storm predict mortality in covid-19. *Journal of Inflammation Research*, *14*, 4651–4667. https://doi.org/10.2147/JIR.S320685

Hodges, G., Pallisgaard, J., Schjerning Olsen, A. M., McGettigan, P., Andersen, M., Krogager, M., Kragholm, K., Køber, L., Gislason, G. H., Torp-Pedersen, C., & Bang, C. N. (2020). Association between biomarkers and COVID-19 severity and mortality: A nationwide Danish cohortstudy. *BMJ Open*, *10*(12). https://doi.org/10.1136/bmjopen-2020-041295

Huang, I., Pranata, R., Lim, M. A., Oehadian, A., & Alisjahbana, B. (2020). C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. *Therapeutic Advances in Respiratory Disease*, *14*. https://doi.org/10.1177/1753466620937175

Huang, J., Kays, K., Lavin-Parsons, K., Parry, lair, Lilley, B., Lodenstein, C., McKaig, B., Charland, N., Khanna, H., Margolin, J., team Moshe Sade-Feldman, processing, Gonye, A., Gushterova, I., Lasalle, T., Sharma, N., Russo, B. C., Rojas-Lopez, M., Manakongtreecheep, K., Tantivit, J., & Fisher Thomas, M. (n.d.). *Identifying Common Biomarkers Between COVID-19 and Commonly Associated Comorbidities*. https://doi.org/10.1101/2020.10.02.20205609

K Geetha, R. (2021). Biomarkers in Covid-19 Diagnosis. *Archive of Biochemistry*, 001–002. https://doi.org/10.17352/ab.000004

Khan, M., Shah, N., Mushtaq, H., & Jehanzeb, V. (2021a). Profiling Laboratory Biomarkers Associated with COVID-19 Disease Progression: A Single-Center Experience. *International Journal of Microbiology*, *2021*, 1–7. https://doi.org/10.1155/2021/6643333

Khan, M., Shah, N., Mushtaq, H., & Jehanzeb, V. (2021b). Profiling Laboratory Biomarkers Associated with COVID-19 Disease Progression: A Single-Center Experience. *International Journal of Microbiology*, *2021*, 1–7. https://doi.org/10.1155/2021/6643333

Kimura, Y., Nakai, Y., Shin, J., Hara, M., Takeda, Y., Kubo, S., Jeremiah, S. S., Ino, Y., Akiyama, T., Moriyama, K., Sakai, K., Saji, R., Nishii, M., Kitamura, H., Murohashi, K., Yamamoto, K., Kaneko, T., Takeuchi, I., Hagiwara, E., … Ryo, A. (2021). Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach. *Scientific Reports*, *11*(1). https://doi.org/10.1038/s41598-021-98253-9

Kong, Y., Han, J., Wu, X., Zeng, H., Liu, J., & Zhang, H. (2020). VEGF-D: A novel biomarker for detection of COVID-19 progression. *Critical Care*, *24*(1). https://doi.org/10.1186/s13054-020-03079-y

Leulseged, T. W., Hassen, I. S., Ayele, B. T., Tsegay, Y. G., Abebe, D. S., Edo, M. G., Maru, E. H., Zewde, W. C., Naylor, L. K., Semane, D. F., Dresse, M. T., & Tezera, B. B. (2021). Laboratory biomarkers of covid-19 disease severity and outcome: Findings from a developing country. *PLoS ONE*, *16*(3 March). https://doi.org/10.1371/journal.pone.0246087

Lima, W. G., Barra, A., Brito, J. C. M., & Nizer, W. S. C. (2020). D-Dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: a meta-analysis. *Blood Coagulation & Fibrinolysis : An International Journal in Haemostasis and Thrombosis*, *31*(5), 335–338. https://doi.org/10.1097/MBC.0000000000000927

Liu, Y. C., Kuo, R. L., & Shih, S. R. (2020). COVID-19: The first documented coronavirus pandemic in history. In *Biomedical Journal* (Vol. 43, Issue 4, pp. 328–333). Elsevier B.V. https://doi.org/10.1016/j.bj.2020.04.007

Malik, P., Patel, U., Mehta, D., Patel, N., Kelkar, R., Akrmah, M., Gabrilove, J. L., & Sacks, H. (2021). Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis. In *BMJ Evidence-Based Medicine* (Vol. 26, Issue 3, pp. 107–108). BMJ Publishing Group. https://doi.org/10.1136/bmjebm-2020-111536

Marimuthu, A., Anandhan, M., Sundararajan, L., Chandrasekaran, J., & Ramakrishnan, B. (2021). Utility of various inflammatory markers in predicting outcomes of hospitalized patients with COVID-19 pneumonia: A single-center experience. *Lung India*, *38*(5), 448–453. https://doi.org/10.4103/lungindia.lungindia_935_20

Montesarchio, V., Parella, R., Iommelli, C., Bianco, A., Manzillo, E., Fraganza, F., Palumbo, C., Rea, G., Murino, P., de Rosa, R., Atripaldi, L., D'Abbraccio, M., Curvietto, M., Mallardo, D., Celentano, E., Grimaldi, A. M., Palla, M., Trojaniello, C., Vitale, M. G., … Ascierto, P. A. (2020). Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. *Journal for ImmunoTherapy of Cancer*, *8*(2). https://doi.org/10.1136/jitc-2020-001089

Morell-Garcia, D., Ramos-Chavarino, D., Bauça, J. M., Argente del Castillo, P., Ballesteros-Vizoso, M. A., García de Guadiana-Romualdo, L., Gómez-Cobo, C., Pou, J. A., Amezaga-Menéndez, R., Alonso-Fernández, A., Llompart, I., & García-Raja, A. (2021). Urine biomarkers for the prediction of mortality in COVID-19 hospitalized patients. *Scientific Reports*, *11*(1). https://doi.org/10.1038/s41598-021-90610-y

Mueller, C., Giannitsis, E., Jaffe, A. S., Huber, K., Mair, J., Cullen, L., Hammarsten, O., Mills, N. L., Möckel, M., Krychtiuk, K., Thygesen, K., & Lindahl, B. (2021). Cardiovascular

biomarkers in patients with COVID-19. *European Heart Journal. Acute Cardiovascular Care*, *10*(3), 310–319. https://doi.org/10.1093/ehjacc/zuab009

Omland, T., Mills, N. L., & Mueller, C. (2021). Cardiovascular biomarkers in COVID-19. *European Heart Journal. Acute Cardiovascular Care*, *10*(5), 473–474. https://doi.org/10.1093/ehjacc/zuab037

Ouahmi, H., Courjon, J., Morand, L., François, J., Bruckert, V., Lombardi, R., Esnault, V., Seitz-Polski, B., Demonchy, E., Dellamonica, J., & Boyer-Suavet, S. (2021). Proteinuria as a Biomarker for COVID-19 Severity. *Frontiers in Physiology*, *12*. https://doi.org/10.3389/fphys.2021.611772

Pu, J., Leader, J., Bandos, A., Shi, J., Du, P., Yu, J., Yang, B., Ke, S., Guo, Y., Field, J. B., Fuhrman, C., Wilson, D., Sciurba, F., & Jin, C. (n.d.). *Any unique image biomarkers associated with COVID-19? Abbreviations AUC Area under the curve BCE Binary cross-entropy CAP Community-acquired pneumonia CI Confidencial interval CNN Convolutional neural network COVID-19 Novel coronavirus CT Computed tomography FC Fully connected GPU Graphics processing unit IRB Institutional review boards ROC Receiver operating characteristic*. https://doi.org/10.1007/s00330-020-06956-w/Published

Richards, O., Pallmann, P., King, C., Cheema, Y., Killick, C., Thomas-Jones, E., Harris, J., Bailey, C., & Szakmany, T. (2021). Procalcitonin increase is associated with the development of critical care-acquired infections in covid-19 ards. *Antibiotics*, *10*(11). https://doi.org/10.3390/antibiotics10111425

Rochwerg, B., Siemieniuk, R., & Jacobs, M. (2021). *Therapeutics and COVID-19 LIVING GUIDELINE 24 SEPTEMBER 2021*.

Sabaka, P., Koščálová, A., Straka, I., Hodosy, J., Lipták, R., Kmotorková, B., Kachlíková, M., & Kušnírová, A. (2021). Role of interleukin 6 as a predictive factor for a severe course of

Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. *BMC Infectious Diseases*, *21*(1). https://doi.org/10.1186/s12879-021-05945-8

Santa Cruz, A., Mendes-Frias, A., Oliveira, A. I., Dias, L., Matos, A. R., Carvalho, A., Capela, C., Pedrosa, J., Castro, A. G., & Silvestre, R. (2021). Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. *Frontiers in Immunology*, *12*. https://doi.org/10.3389/fimmu.2021.613422

Sheth, A., Modi, M., Dawson, D., & Dominic, P. (2021). Prognostic value of cardiac biomarkers in COVID-19 infection. *Scientific Reports*, *11*(1). https://doi.org/10.1038/s41598-021-84643-6

Shih, H. I., Wu, C. J., Tu, Y. F., & Chi, C. Y. (2020). Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. In *Biomedical Journal* (Vol. 43, Issue 4, pp. 341–354). Elsevier B.V. https://doi.org/10.1016/j.bj.2020.05.021

Sivakorn, C., Dechsanga, J., Jamjumrus, L., Boonnak, K., Schultz, M. J., Dondorp, A. M., Phumratanaprapin, W., Ratanarat, R., Naorungroj, T., Wattanawinitchai, P., Siripoon, T., Duangdee, C., & Techarang, T. (2021). High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically Ill COVID-19 Patients. *American Journal of Tropical Medicine and Hygiene*, *105*(1), 73–80. https://doi.org/10.4269/ajtmh.21-0165

Song, X., Ji, J., Reva, B., Joshi, H., Calinawan, A. P., Mazumdar, M., Wisnivesky, J. P., Taioli, E., Wang P., Veluswamy, R. R. (2021). Post-anticoagulant d-dimer is a highly prognostic biomarker of covid-19 mortality. *ERJ Open Research*, *7*(3). https://doi.org/10.1183/23120541.00018-2021

Sorić Hosman, I., Kos, I., & Lamot, L. (2021). Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. In *Frontiers in Immunology* (Vol. 11). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2020.631299

Stefanini, G. G., Chiarito, M., Ferrante, G., Cannata, F., Azzolini, E., Viggiani, G., de Marco, A., Briani, M., Bocciolone, M., Bragato, R., Corrada, E., Gasparini, G. L., Marconi, M., Monti, L., Pagnotta, P. A., Panico, C., Pini, D., Regazzoli, D., My, I., … Condorelli, G. (2020). Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. *Heart*, *106*(19), 1512–1518. https://doi.org/10.1136/heartjnl-2020-317322

Sun, B., Tang, N., Peluso, M. J., Iyer, N. S., Torres, L., Donatelli, J. L., Munter, S. E., Nixon, C. C., Rutishauser, R. L., Rodriguez-Barraquer, I., Greenhouse, B., Kelly, J. D., Martin, J. N., Deeks, S. G., Henrich, T. J., & Pulliam, L. (2021). Characterization and biomarker analyses of post-covid-19 complications and neurological manifestations. *Cells*, *10*(2), 1–18. https://doi.org/10.3390/cells10020386

Tabassum, T., Rahman, A., Araf, Y., Ullah, M. A., & Hosen, M. J. (2021). Prospective selected biomarkers in COVID-19 diagnosis and treatment. In *Biomarkers in Medicine* (Vol. 15, Issue 15, pp. 1435–1449). Future Medicine Ltd. https://doi.org/10.2217/bmm-2021-0038

Tang, B., Shojaei, M., Wang, Y., Nalos, M., McLean, A., Afrasiabi, A., Kwan, T. N., Kuan, W. sen, Zerbib, Y., Herwanto, V., Gunawan, G., Bedognetti, D., Zoppoli, G., Ballestrero, A., Rinchai, D., Cremonesi, P., Bedognetti, M., Matejovic, M., Karvunidis, T., … Weng, S. (2021). Prospective validation study of prognostic biomarkers to predict adverse outcomes in patients with COVID-19: A study protocol. *BMJ Open*, *11*(1). https://doi.org/10.1136/bmjopen-2020-044497

Tom, J., Bao, M., Tsai, L., Qamra, A., Summers, D., Carrasco-Triguero, M., Mcbride, J., Rosenberger, C. M., Lin, C. J. F., Stubbings, W., Blyth, K. G., Carratalà, J., François, B.,

Benfield, T., Haslem, D., Bonfanti, P., van der Leest, C. H., Rohatgi, N., Wiese, L., … Cai, F. (2021). *possibly resulting in more severe clinical*. https://doi.org/10.1097/CCM.0000000000005229

Ullah, W., Thalambedu, N., Haq, S., Saeed, R., Khanal, S., Tariq, S., Roomi, S., Madara, J., Boigon, M., Haas, D. C., & Fischman, D. L. (2020). Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19. *Journal of Community Hospital Internal Medicine Perspectives*, *10*(5), 402–408. https://doi.org/10.1080/20009666.2020.1798141

Valerio, L., Ferrazzi, P., Sacco, C., Ruf, W., Kucher, N., Konstantinides, S. v., Barco, S., & Lodigiani, C. (2021). Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. In *Thrombosis and Haemostasis* (Vol. 121, Issue 1, pp. 98–101). Georg Thieme Verlag. https://doi.org/10.1055/s-0040-1721317

Wendel Garcia, P. D., Fumeaux, T., Guerci, P., Heuberger, D. M., Montomoli, J., Roche-Campo, F., Schuepbach, R. A., & Hilty, M. P. (2020). Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. *EClinicalMedicine*, *25*. https://doi.org/10.1016/j.eclinm.2020.100449

Whetton, A. D., Preston, G. W., Abubeker, S., & Geifman, N. (2020). Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease. In *Journal of Proteome Research* (Vol. 19, Issue 11, pp. 4219–4232). American Chemical Society. https://doi.org/10.1021/acs.jproteome.0c00326

Xu, Y., Baylink, D. J., Chen, C. S., Reeves, M. E., Xiao, J., Lacy, C., Lau, E., & Cao, H. (2020). The importance of Vitamin D metabolism as a potential prophylactic, immunoregulatory

and neuroprotective treatment for COVID-19. In *Journal of Translational Medicine* (Vol. 18, Issue 1). BioMed Central. https://doi.org/10.1186/s12967-020-02488-5

Yael Becher, Leonid Goldman, Nadav Schacham, Irina Gringauz, & Dan Justo. (2020). D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients. *European Journal of Case Reports in Internal Medicine*, *LATEST ONLINE*. https://doi.org/10.12890/2020_001725

Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., Chen, X., Chen, S., Yu, K., Huang, Z., & Hu, B. (2020). D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case control study. *Journal of Intensive Care*, *8*(1). https://doi.org/10.1186/s40560-020-00466-z

Ye, W., Chen, G., Li, X., Lan, X., Ji, C., Hou, M., Zhang, D., Zeng, G., Wang, Y., Xu, C., Lu, W., Cui, R., Cai, Y., Huang, H., & Yang, L. (2020). Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. *Respiratory Research*, *21*(1). https://doi.org/10.1186/s12931-020-01428-7

Zakeri, R., Pickles, A., Carr, E., Bean, D. M., O'Gallagher, K., Kraljewic, Z., Searle, T., Shek, A., Galloway, J. B., Teo, J. T. H., Shah, A. M., Dobson, R. J. B., & Bendayan, R. (2021). Biological responses to COVID-19: Insights from physiological and blood biomarker profiles. *Current Research in Translational Medicine*, *69*(2). https://doi.org/10.1016/j.retram.2021.103276

Zhang, S., Qu, R., Wang, P., & Wang, S. (2021). Identification of Novel COVID-19 Biomarkers by Multiple Feature Selection Strategies. *Computational and Mathematical Methods in Medicine*, *2021*. https://doi.org/10.1155/2021/2203636

Zhang, Y., Wang, D., Lin, M., Sun, T., Chen, J., Xu, J., Zhu, H., Zhu, G., Lu, R., Hong, L., Shen, B., Wu, X., & Zheng, Y. (2020). *Serum Amyloid A Protein as a Potential Biomarker*

Useful in Monitoring the Course of COVID-19 : A Retrospectively Studied. https://doi.org/10.21203/rs.3.rs-19724/v1

Zildzic, M., Masic, I., Salihefendic, N., Jasic, M., & Hajdarevic, B. (2020). The Importance of Nutrition in Boosting Immunity for Prevention and Treatment COVID-19. *International Journal on Biomedicine and Healthcare*, *8*(2), 73. https://doi.org/10.5455/ijbh.2020.8.73-79

Zinellu, A., Paliogiannis, P., Carru, C., & Mangoni, A. A. (2021). Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis. In *International Journal of Infectious Diseases* (Vol. 105, pp. 668–674). Elsevier B.V. https://doi.org/10.1016/j.ijid.2021.03.025